King’s Dubai adds 100 beds by 2028: the numbers behind the expansion

King’s College Hospital London - Dubai is adding 100 beds to reach 200 beds by 2028, which makes the Phase 2 project a direct capacity and oncology play for Dubai Hills rather than a simple real estate expansion.

The highest-stakes readers are CEOs, CFOs and COOs of Dubai hospitals. The project changes the private tertiary care map in a corridor that already pulls insured patients from Dubai Hills, Al Barsha, Umm Suqeim, Arabian Ranches and parts of New Dubai. For competitors, the deal to watch is the mix of beds, radiation oncology, critical care and insurer access, not the groundbreaking ceremony.

The numbers that matter

The hard figures are limited but useful. Emirates 24|7 reported that the ceremony took place on 23 September 2026, Phase 2 is scheduled for completion in 2028, and the hospital will increase to 200 beds. That implies an added 100-bed block on top of the original Dubai Hills hospital.

The capital cost for Phase 2 was not disclosed. The last public benchmark is the original Dubai Hills facility, described by King’s in 2019 as a 100-bed hospital costing $200 million, or about AED 734 million at the fixed dirham peg. That is a historical benchmark, not a Phase 2 budget. CFOs should ask for the new split between shell-and-core works, medical equipment, radiation shielding, ICU fit-out and working capital before comparing this project with a greenfield hospital.

• Capacity: 100 additional beds, taking Dubai Hills to 200 beds.
• Timing: completion scheduled for 2028, giving rivals roughly two budget cycles to respond.
• Service line: radiation oncology is the most material clinical addition.
• Contractors: DCIB Construction LLC is main contractor with Menasco Mechanical Contracting LLC as joint venture partner.

Why radiation oncology changes the economics

Radiation oncology is the number that does not appear in the headline. It moves King’s closer to a full cancer pathway inside one hospital. That matters for payor contracting, referral retention, imaging demand, chemotherapy adjacency, and inpatient capture after complex surgery.

"With the addition of radiation oncology," said Kimberley Pierce, CEO of King’s College Hospital London - Dubai.

For COOs, the regulatory frame is clear. Dubai facilities sit under the Dubai Health Authority (DHA). The DHA Standards for Oncology Services carry an effective date of 2 June 2024 and list radiotherapy services, treatment planning rooms, mould rooms, chemotherapy services, tumour boards, diagnostic imaging and support areas within oncology service requirements. The same DHA document states that radiotherapy equipment needs a bunker and adjacent computer control area, and requires two technologists for each treatment machine.

That turns the expansion into an execution test. A 2028 opening means King’s must line up DHA facility approvals, radiotherapy staffing, physics support, infection control, biomedical engineering and Federal Authority for Nuclear Regulation requirements for ionising radiation. Operators in Abu Dhabi should read this through the Department of Health - Abu Dhabi (DOH) lens. Northern emirates operators should read it through Ministry of Health and Prevention (MOHAP) licensing and referral leakage.

What operators should watch before 2028

CEOs should track where King’s concentrates the new capacity. If the 100 beds are weighted toward oncology, critical care and surgical recovery, the competitive pressure will fall on high-acuity private hospitals rather than day surgery centres. If the beds are more general medical-surgical, the pressure spreads into maternity, paediatrics and orthopaedics.

CFOs should avoid using the 2019 AED 734 million benchmark as a cost estimate for Phase 2. It is more useful as a check on order of magnitude. The right diligence list is shorter: requested bed mix in DHA filings, linear accelerator count if disclosed, ICU bed count, payor network status, and whether radiation oncology is bundled into oncology packages or billed as standalone episodes.

CMOs should treat 2027 as the patient acquisition window. Cancer pathways are sticky. Once patients enter diagnosis, imaging, surgery, chemotherapy and radiotherapy under one brand, referral leakage declines. Competing providers need named tumour boards, transparent second-opinion routes and insurer-specific access pathways before King’s opens the additional capacity.

For verification, start with DHA’s Health Facility Guidelines, DHA’s Sheryan licensing channels, DOH Abu Dhabi standards for Abu Dhabi assets, and MOHAP facility licensing for northern emirates assets. To compare licensed providers by emirate and category, use the UAE Open Healthcare Directory.